Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Bullboard Posts
Post by toade1313on Jul 10, 2019 7:47am
106 Views
Post# 29902751

Our Only Competition Is Ourselves

Our Only Competition Is OurselvesIn rereading the June 26th PR about the 'new and improved TLC 3200' , it states that until the new version gets the ITA and REB from each site the enrolled patients can be treated with the currently approved version. Here's where the competition from Ourselves comes. The PR then goes on to state 6 great advantages of waiting for the NEW TLC 3200 to come out. What it doesn't state is that the ITA and REB news approvals may take awhile. Here's where the summer vacation delays come in. It's not the doctors who will treat the patients it's the administrators who don't have a vested interest in a quick approval. Our potential patients for our ph2 trial are facing stiff competition from that Theralase company that offers this greatly improved equipment and procedure BUT at a future date. Meanwhile, NO PR yet that any patients have been treated with the current TLC3200.
Bullboard Posts